Immix Biopharma, Inc. (IMMX) stock
Close on Nov 12, 2026Market cap $577.32MP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Sep 30, 2026
Valuation
- Market cap
- $577.32M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 1.72
- Dividend yield
- –
- Free cash flow yield
- -7.84%
Fundamentals
- Net income
- -$46.22M
- EPS, diluted
- -$0.81
- Free cash flow
- -$45.24M
- Book value per share
- $4.52
- Diluted shares
- 74M
Trading
- Previous close
- $8.66
- Open
- $8.40
- Day's range
- $8.06 – $8.50
- Volume
- 960,301
- Average volume (20 days)
- 1,218,249
- Index membership
- Russell 2000 (since Jun 2026)
- Beta (5 years)
- 0.96
- 52-week range
- $3.26 – $15.10
- RSI (14 days)
- 44.5
- Volatility (1 year)
- 84.6%
- Relative volume
- 0.62×
- WACC
- 9.8%
On 3 of our idea lists: More cash than they're worth, Institutions accumulating, Most shorted (a warning list)
Index membership is inferred from the holdings of funds that track each index (IWM), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2021, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | IMMX | S&P 500 | Difference | IMMX per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -12.8% | -2.7% | −10.1 pts | ||
| 3 months | -29.0% | -1.7% | −27.3 pts | ||
| Year to date | +54.3% | +11.9% | +42.4 pts | ||
| 1 year | +116.9% | +12.0% | +104.9 pts | ||
| 3 years | +92.6% | +78.2% | +14.4 pts | +24.4% | +21.2% |
Seven years at a glance
Fiscal years 2019 to 2025 and trailing twelve months, USD
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Immix Biopharma filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- News
- Update
- News
- Update
- Update
About Immix Biopharma
Pharmaceutical Preparations
Immix Biopharma, Inc. is a clinical-stage biopharmaceutical company that develops chimeric antigen receptor cell therapies to treat light chain amyloidosis and other serious medical conditions. Its research focuses on utilizing its proprietary cell therapy platform to create therapeutic candidates. The company's lead product candidate is NXC-201, an investigational cell therapy designed for individuals suffering from relapsed or refractory light chain amyloidosis. Immix Biopharma operates in the biopharmaceutical industry and directs its therapeutic programs toward patient populations diagnosed with these critical disorders.
Company profile, executives and historyImmix Biopharma stock: common questions
What is Immix Biopharma's stock price?
IMMX closed at $8.07 on Nov 12, 2026, down 6.81% on the day. Over the past 52 weeks it traded between $3.26 and $15.10.
What is Immix Biopharma's market cap?
Immix Biopharma was worth $577.32M at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is IMMX's P/E ratio?
Immix Biopharma lost money over the twelve months to Sep 30, 2026 (diluted EPS -$0.81), so it has no meaningful P/E ratio.
Does Immix Biopharma pay a dividend?
No. Immix Biopharma has not paid a cash dividend over the last twelve months.
How has IMMX stock performed over the past year?
Including dividends, IMMX returned +116.9% over the past year, against +12.0% for the S&P 500.
How many IMMX shares are sold short?
11M shares were sold short at the latest FINRA report, 18.96% of the float, or 9.2 days of average trading volume.
Who are Immix Biopharma's competitors?
Companies most similar to Immix Biopharma by business, industry and size include LRMR, RNAC, NKTX, LYEL, CLRB.
See a number that looks wrong?